Exploratory Analyses from the Phase Three INDIGO Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With Vorasidenib

Author:Peters, Katherine   Mellinghoff, Ingo   Wick, Wolfgang   Van Den Bent, Martin   Blumenthal, Deborah   Touat, Mehdi   Clarke, Jennifer   Mendez, Joe   Welsh, Liam   Mason, Warren   Hottinger, Andreas   Sepulveda, Juan   Soffietti, Riccardo   Zhao, Dan   Yi, Denise   Weidl, Daniel   Steelman, Lori   Hassan, Islam   Wen, Patrick   Cloughesy, Timothy   

Session Name:S28: Neuro-oncology: Clinical and Practice Updates  

Topic:Neuro-oncology  

Program Number:S28.002  

Author Institution:Duke University Medical Center, Durham, NC  Memorial Sloan Kettering Cancer Center, New York, NY  Universitätsklinikum Heidelberg, Heidelberg & German Cancer Research Center, Heidelberg, Germany  Erasmus Medical Center, Rotterdam, Netherlands  Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel  Pitié Salpêtrière Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP) Sorbonne Université, Paris, France  UCSF, San Francisco, CA  Huntsman Cancer, Salt Lake City, UT  The Royal Marsden Hospital, London, United Kingdom  Toronto General Hospital, Toronto, ON, Canada  University Hospital of Lausanne, Lausanne, Switzerland  Hospital Universitario 12 de Octubre, Madrid, Spain  University of Turin, Torino, Italy  Servier Pharmaceuticals, CAMBRIDGE, MA  Servier Pharmaceuticals, Boston, MA  Servier Deutschland GmbH, Munich, Germany  Servier Pharmaceuticals, Wilmington, MA  Dana-Farber/Brigham and Women'S Cancer Center, Boston, MA  University of California Los Angeles, Los Angeles, CA  

Characterizing Patients on Memantine and Their Response to Treatment for Post Traumatic Headache

Design of Phase Three of KYSA-6, a Global Open-label, Randomized, Controlled Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, Versus Ongoing Standard-of-Care (SOC) Immunosuppressive Therapy in Generalized Myasthenia Gr

Author:Mupiddi, Sri   Hunter, Michael C   Hoffmann, Sarah   Hegelmaier, Tobias   Motte, Jeremias   Gold, Ralf   Mougiakakos, Dimitrios   Schubert, Charlotte   Schreiber, Stefanie   Habib, Ali   Geis, Christian   Carbunar, Olimpia   Shroff, Sheetal   Dalakas, Marinos   Berthele, Achim   Shieh, Perry   Barboi, Alexandru   Dutra, Livia   Alsolaihim, Alanood   Needham, Edward   Norwood, Fiona   Cutter, Gary R   Hunter, Brad   Chou, Justin   Xing, Baodong   Borie, Dominic   Gehchan, Naji   Haghikia, Aiden   

Session Name:P9: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis Clinical Trials  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P9.011  

Author Institution:Stanford, CA  Intermountain Medical Center, UT  Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany  Hannover Medical School, Germany  Ruhr University Bochum, Germany  Otto von Guericke University Magdeburg, Magdeburg, Germany  University Medical Center Hamburg-Eppendorf, Germany  Otto-von-Guericke University Magdeburg, Germany  University of California, Irvine, Orange, CA  Jena University Hospital, Germany  University of Miami, Miami, FL  Houston Methodist Hospital, Houston, TX  Thomas Jefferson University, Philadelphia, PA  School of Medicine, Technical University Munich, Klinikum rechts der Isar, Dept., Muenchen, Germany  University of California Los Angeles, Los Angeles, CA  Indiana University Health, IN  Instituto do Cérebro do Hospital Israelita Albert Einstein, Brazil  King Faisal Specialist Hospital and Research Center, Saudi Arabia  University of Cambridge, United Kingdom  Kings College Hospital, United Kingdom  University of Alabama , AL  Intermountain Health, UT  Kyverna Therapeutics Inc., CA  Kyverna Therapeutics Inc., Emeryville, CA  Hannover Medical School, Hannover, Germany